R&D Engineering Intern @ Inogen

Description

R&D Engineering Intern – RTM

Role Overview

The R&D Engineering Intern – RTM will contribute directly to Inogen’s next-generation Remote Therapeutic Monitoring (RTM) ecosystem by building data-driven insights, prototype app features, and analytics tools that support Inogen’s respiratory products.

This role is hands-on and tactical, and ideal for students who want to apply data science and digital health design skills in a real medical device environment.

Key Responsibilities & Tactical Deliverables

Patient-Facing App Prototyping

Assist in creating low-fidelity wireframes for an RTM mobile app (usage tracking, symptom entry, reminders, progress screens).
Deliverable: A clickable prototype (Figma or similar) showing at least three user flows.
Prototype simple rule-based digital nudges (e.g., reminders triggered when usage is low or symptoms worsen).
Deliverable: A logic map and sample message library for patient engagement.

Connected Care Model Mapping

Map the end-to-end digital patient journey for RTM: device activation ? data ? patient-reported outcomes (PROs) ? provider dashboards.
Deliverable: A visual, single-slide workflow showing data touchpoints and RTM billing considerations.

RTM / RPM Metric Design

Define the minimum set of patient-reported outcomes (PROs) for COPD and bronchiectasis RTM.
Deliverable: A PRO list with a proposed scoring rubric for Inogen’s digital health platform.
Propose adherence and response KPIs for internal dashboards (e.g., adherence percentage, symptom stability, session variability).
Deliverable: A dashboard mockup in Power BI, Tableau, or Figma.

Ideal Background

Education

Pursuing a Bachelor’s or Master’s degree in:

Data Science
Computer Science
Biomedical Engineering
Health Informatics
Public Health
Or related fields

Experience (Academic or Project-Based)

Python (pandas, NumPy, matplotlib, seaborn)
Basic UI/UX prototyping tools (Figma, Sketch, etc.)
Data visualization and analytics
Interest in digital health, respiratory care, medical devices, or patient-centered design
Strong writing and communication skills

What the Intern Will Gain

Practical experience applying data science to real-world medical device telemetry
Exposure to RTM/RPM workflows, clinical pathways, and patient-reported outcomes
Experience creating prototype digital health application flows
Understanding of how digital tools integrate with respiratory therapy (POCs, SOCs, Simeox, and future sensors)
A portfolio of code notebooks, prototypes, dashboards, and technical briefs suitable for resumes, graduate school applications, or industry roles
Direct collaboration with R&D, Product, Clinical, and Digital Health teams within a regulated medical device environment

Inogen assesses market data to ensure a competitive compensation package for our employees. The base salary for this position is expected to be between $21.19 and $23.37 per hour. However, actual base salary if hired will be determined on an individualized basis and will be based on non-discriminatory factors, including as to individual skills, education, experience and market location.

Inogen is an Equal Employment Opportunity/Affirmative Action Employer - Underrepresented racial and ethnic groups/Females/Individuals with Disabilities/Protected Veterans.

About the company

Inogen makes and sells portable oxygen concentrators for people with chronic breathing problems like COPD. These devices pull in air from the surroundings, remove nitrogen, and deliver concentrated oxygen to the user, allowing them to move around and stay independent while receiving oxygen therapy. The product is designed to be light and easy to carry, with models available to buy or rent directly from Inogen, and through a network of distributors and home medical equipment providers. What sets Inogen apart is its direct-to-consumer approach (and rental option) that bypasses traditional durable medical equipment sellers, aiming to build direct relationships with patients. The company operates in the home medical equipment market, targeting those who need long-term oxygen therapy. Its goal is to improve patients’ quality of life by providing portable, user-friendly oxygen solutions and expanding access to oxygen therapy.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Goleta, CA

Founded

2001

Get referred to Inogen

See people who can refer or advise you

Simplify's Take

What believers are saying

Q2 2026 revenue rose 3.0% to $95.1 million; adjusted EBITDA turned positive at $2.4 million.
The September 2026 Rotech sale simplifies operations and adds up to $25 million cash.
Yuwell's 9.9% strategic stake and 2026 buyback authorization reinforce capital access and international expansion.

What critics are saying

U.S. rental revenue fell 9.8% in first-half 2026; divestiture signals structural weakness, not recovery.
Third-quarter 2026 revenue will roughly match 2025, showing U.S. channel mix still suppresses growth.
If Rotech integration or reimbursement shifts stall, Inogen loses rental cash flow and investor confidence.

What makes Inogen unique

Inogen owns a focused respiratory platform, now anchored by portable oxygen concentrators and supply contracts.
Rotech distribution plus direct-to-consumer cash-pay channels give Inogen two separate patient acquisition engines.
International POC expansion delivered 14.8% revenue growth in Q2 2026, supporting global brand reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan
401(k) Company Match

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth

Business Wire

Sep 30th, 2026

Inogen sells US oxygen rental business to Rotech for $25M, boosts buyback by $15M

Inogen has agreed to sell its US oxygen rental business to Rotech Healthcare for up to $25 million in cash. The transaction is expected to close in the fourth quarter of 2026, subject to customary closing conditions. The medical technology company also signed a long-term supply agreement with Rotech, which will distribute Inogen's oxygen concentrators through its national network. The rental business generated $24.3 million in revenue during the first half of 2026, down 9.8% year-over-year. Following the deal, Inogen will focus on a streamlined commercial model whilst partnering with home medical equipment providers. The company expects the transaction to increase both revenue growth and adjusted operating income. Inogen's board has approved a $15 million increase to its share repurchase authorisation, bringing the total to $45 million.

Yahoo Finance

Aug 10th, 2026

Inogen Q2 earnings beat estimates as sales rise 3% Y/Y to $95.1M, but 2026 outlook cut

Inogen reported breakeven earnings for Q2 2026, beating the Zacks Consensus Estimate by 17.7%. This compares to an adjusted loss of 2 cents per share in the prior-year quarter. Revenues reached $95.1 million, up 3% year over year and slightly ahead of estimates. The growth was driven by strong international demand for portable oxygen concentrators, favourable exchange rates and new product contributions. International sales climbed 14.8% to $41.3 million, marking the 10th consecutive quarter of double-digit growth. However, US sales declined 2.3% to $42.3 million, whilst US rental revenues fell 11.8% to $11.6 million. Adjusted gross margin improved 65 basis points to 45.6%, driven by cost improvements and lower warranty expenses. Year to date, Inogen's shares have fallen 10%.

Yahoo Finance

Aug 7th, 2026

Inogen raises 2026 EBITDA guidance to $4M on 15% international growth despite US sales headwinds

Inogen reported strong international revenue growth of 15% year-over-year in Q2 2026, marking its 10th consecutive quarter of double-digit international growth. The company's core portable oxygen concentrator unit volume grew over 12%, outpacing overall market growth. Gross margin expanded by 65 basis points to 45.6%, driven by cost improvements and lower warranty expenses. Inogen raised its full-year adjusted EBITDA guidance to approximately $4 million, representing 48% growth over 2025. However, the company lowered its full-year revenue guidance to $355–361 million from $366–373 million. US sales declined 2% year-over-year due to channel mix challenges, whilst US rental revenue decreased 12%. New products Voxy and Aurora are gaining traction, with Voxy shipping over 5,000 units. Inogen maintains a strong balance sheet with $106.8 million in cash and no debt.

Startup Rise Asia

Jul 23rd, 2026

Yuwell Medical invests $27M in US respiratory firm Inogen, targets top three global ranking

Yuwell Medical has announced a strategic investment in Inogen, a US-based respiratory health company. Through its Hong Kong subsidiary, Yuwell will invest approximately $27.2 million for a 9.9% stake in Inogen's common stock. The partnership will focus on four key areas: international distribution, trademark licensing, joint research and development, and supply chain optimisation. Both companies specialise in oxygen concentrators and aim to combine their expertise across different markets. At Yuwell's 2025 Global Core Partner Conference, Chairman Alex Wu outlined the company's five-year vision to become one of the top three global players in home medical health. Yuwell identified respiratory treatment solutions, diabetes care, and emergency services as its three strategic priorities for international expansion.

Associated Press

Jul 1st, 2026

Inogen appoints Andy Reding as chief operating officer to drive growth and profitability

Inogen, a medical technology company specialising in respiratory products, has appointed Andy Reding as Chief Operating Officer, effective 6 July 2026. Reding will oversee revenue and operational performance whilst aligning cross-functional priorities as the company pursues new product launches and geographic expansion. Reding brings over 30 years of experience in medical technology. Most recently, he served as Chief Commercial Officer at Viant Medical for six years, where he led teams across 25 facilities. He previously held leadership roles at Hillrom Respiratory Health, managing sales, marketing and product development. As part of his employment, Reding will receive 130,000 restricted stock units vesting over three years. He holds an MBA from the University of South Carolina and a bachelor's degree from Marquette University.

Inogen

R&D Engineering Intern - Remote Therapeutic Monitoring

About the job